MX2018012265A - Receptores de celulas t. - Google Patents
Receptores de celulas t.Info
- Publication number
- MX2018012265A MX2018012265A MX2018012265A MX2018012265A MX2018012265A MX 2018012265 A MX2018012265 A MX 2018012265A MX 2018012265 A MX2018012265 A MX 2018012265A MX 2018012265 A MX2018012265 A MX 2018012265A MX 2018012265 A MX2018012265 A MX 2018012265A
- Authority
- MX
- Mexico
- Prior art keywords
- tcrs
- cells
- cell receptors
- nucleic acids
- mage
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 8
- 210000004027 cell Anatomy 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención está relacionada con receptores de células T (TCRs) los cuales se unen al péptido restringido de HLA-A*0201 GVYDGEEHSV (SEQ ID NO: 1) derivado de la proteína MAGE-B2. Los TCRs de la invención demuestran excelentes perfiles de especificidad para este epitope de MAGE. También se proporcionan ácidos nucleicos que codifican los TCRs, células diseñadas para presentar los TCRs, células que albergan vectores de expresión que codifican los TCRs y composiciones farmacéuticas que comprenden los TCRs, ácidos nucleicos o células de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201606172 | 2016-04-08 | ||
PCT/EP2017/058576 WO2017174822A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012265A true MX2018012265A (es) | 2019-02-07 |
Family
ID=58701591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012265A MX2018012265A (es) | 2016-04-08 | 2017-04-10 | Receptores de celulas t. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20190135892A1 (es) |
EP (2) | EP4389898A2 (es) |
JP (2) | JP7179616B2 (es) |
KR (1) | KR20190059874A (es) |
CN (2) | CN117603339A (es) |
AU (2) | AU2017248120B2 (es) |
BR (1) | BR112018070600A2 (es) |
CA (1) | CA3020530A1 (es) |
IL (1) | IL262146A (es) |
MX (1) | MX2018012265A (es) |
RU (1) | RU2018138836A (es) |
SG (1) | SG11201808709VA (es) |
WO (1) | WO2017174822A1 (es) |
ZA (1) | ZA201806865B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
MA49156A (fr) | 2014-12-23 | 2020-03-25 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
CA3020058A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
JP7204484B2 (ja) | 2016-04-08 | 2023-01-16 | アダプティミューン・リミテッド | T細胞受容体 |
EP3692058A1 (en) | 2017-10-06 | 2020-08-12 | Oslo Universitetssykehus HF | Chimeric antigen receptors |
WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
CA3097399A1 (en) * | 2018-04-19 | 2019-10-24 | The Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
JP2021536578A (ja) * | 2018-09-14 | 2021-12-27 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Tcrリガンドの高スループットペプチド−mhc親和性スクリーニングのための方法 |
USD998170S1 (en) * | 2019-04-10 | 2023-09-05 | Inveox Gmbh | Sample container |
CN110172091B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2021028690A1 (en) | 2019-08-13 | 2021-02-18 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
CA3183756A1 (en) * | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
DE60203125T2 (de) | 2001-08-31 | 2006-04-06 | Avidex Ltd., Abingdon | Löslicher t zell rezeptor |
PL2440575T3 (pl) | 2009-06-09 | 2015-04-30 | Vaxon Biotech | Identyfikacja, optymalizacja i stosowanie wspólnych epitopów hla-b*0702 do immunoterapii |
RU2020108070A (ru) * | 2012-07-27 | 2020-03-16 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс | Конструирование t-клеточных рецепторов |
KR102473964B1 (ko) | 2016-04-08 | 2022-12-06 | 이뮤노코어 리미티드 | T 세포 수용체 |
CA3020058A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
JP7204484B2 (ja) | 2016-04-08 | 2023-01-16 | アダプティミューン・リミテッド | T細胞受容体 |
-
2017
- 2017-04-10 CA CA3020530A patent/CA3020530A1/en active Pending
- 2017-04-10 AU AU2017248120A patent/AU2017248120B2/en active Active
- 2017-04-10 SG SG11201808709VA patent/SG11201808709VA/en unknown
- 2017-04-10 EP EP24170484.0A patent/EP4389898A2/en active Pending
- 2017-04-10 KR KR1020187032021A patent/KR20190059874A/ko not_active Application Discontinuation
- 2017-04-10 MX MX2018012265A patent/MX2018012265A/es unknown
- 2017-04-10 JP JP2018552696A patent/JP7179616B2/ja active Active
- 2017-04-10 CN CN202311577769.5A patent/CN117603339A/zh active Pending
- 2017-04-10 EP EP17723015.8A patent/EP3440102B1/en active Active
- 2017-04-10 CN CN201780031672.0A patent/CN110023330B/zh active Active
- 2017-04-10 BR BR112018070600A patent/BR112018070600A2/pt not_active IP Right Cessation
- 2017-04-10 WO PCT/EP2017/058576 patent/WO2017174822A1/en active Application Filing
- 2017-04-10 RU RU2018138836A patent/RU2018138836A/ru unknown
-
2018
- 2018-10-04 IL IL262146A patent/IL262146A/en unknown
- 2018-10-08 US US16/154,161 patent/US20190135892A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06865A patent/ZA201806865B/en unknown
-
2022
- 2022-01-12 US US17/574,152 patent/US20220127327A1/en active Pending
- 2022-07-04 JP JP2022107704A patent/JP7437452B2/ja active Active
- 2022-10-20 AU AU2022256181A patent/AU2022256181B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20190059874A (ko) | 2019-05-31 |
JP7179616B2 (ja) | 2022-11-29 |
RU2018138836A3 (es) | 2020-07-30 |
SG11201808709VA (en) | 2018-11-29 |
JP7437452B2 (ja) | 2024-02-22 |
CN117603339A (zh) | 2024-02-27 |
US20190135892A1 (en) | 2019-05-09 |
RU2018138836A (ru) | 2020-05-12 |
AU2017248120A1 (en) | 2018-11-22 |
EP3440102B1 (en) | 2024-06-05 |
JP2019516355A (ja) | 2019-06-20 |
IL262146A (en) | 2018-11-29 |
BR112018070600A2 (pt) | 2019-02-05 |
WO2017174822A1 (en) | 2017-10-12 |
EP4389898A2 (en) | 2024-06-26 |
JP2022153399A (ja) | 2022-10-12 |
CN110023330A (zh) | 2019-07-16 |
CN110023330B (zh) | 2023-12-12 |
AU2017248120B2 (en) | 2022-07-21 |
CA3020530A1 (en) | 2017-10-12 |
ZA201806865B (en) | 2021-04-28 |
AU2022256181A1 (en) | 2022-11-24 |
US20220127327A1 (en) | 2022-04-28 |
EP3440102A1 (en) | 2019-02-13 |
AU2022256181B2 (en) | 2024-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012268A (es) | Receptores de celulas t. | |
MX2022011309A (es) | Receptores de celulas t. | |
MX2018012265A (es) | Receptores de celulas t. | |
NZ731571A (en) | T cell receptors | |
PH12017501287A1 (en) | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist | |
NZ715038A (en) | T cell receptors | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
MX2018013784A (es) | Proteinas de fusion gdf15 y usos de estas. | |
EA038402B9 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
MY192481A (en) | Factor viii chimeric proteins and uses thereof | |
MX2022005119A (es) | Metodos de reduccion de olor. | |
MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
WO2016130628A8 (en) | Griffithsin mutants | |
PH12015500771A1 (en) | Novel fc gamma receptor iib variants | |
JOP20210326A1 (ar) | أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها | |
WO2015107363A3 (en) | Mycobacterial antigen composition | |
MX2017007105A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
MX2021004925A (es) | Variantes de adn-polimerasa modificadas. | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
MX2017008505A (es) | Composicion. | |
PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
MY191843A (en) | Trehalose phosphorylase | |
EA201692440A1 (ru) | Пролин-специфичная эндопротеаза и ее применение | |
EA039001B9 (ru) | Аденовирусные полинуклеотиды и полипептиды |